Five-Year Sotyktu Data Confirm Long-Term Safety and Efficacy in Plaque Psoriasis
Key Takeaways
•The POETYK PSO long-term extension trial demonstrated that Sotyktu maintains a consistent safety profile over five years.•Clinical responses, including PASI 90, were sustained...
Opdivo Plus Chemotherapy Extends Survival in Resectable NSCLC
Key Takeaways
•The Phase 3 CheckMate -816 trial demonstrated that neoadjuvant Opdivo (nivolumab) combined with chemotherapy significantly improves overall survival in patients with resectable non-small...
FDA Grants Priority Review to Zongertinib for HER2-Mutant Advanced NSCLC
Key Takeaways
•The U.S. Food and Drug Administration (FDA) has granted Priority Review to Boehringer Ingelheim’s new drug application for zongertinib (BI 1810631) as a...
Opdualag Phase 3 Trial Falls Short in Adjuvant Melanoma Treatment
Key Takeaways
•The Phase 3 RELATIVITY-098 trial did not achieve its primary endpoint of recurrence-free survival.•Opdualag’s safety profile remained consistent with existing data.•Opdivo continues as...
ICER, NICE, and Canada’s Drug Agency Form Health Economics Methods Advisory
Key Takeaways
•The Institute for Clinical and Economic Review (ICER), National Institute for Health and Care Excellence (NICE), and Canada’s Drug Agency (CDA-AMC) have established...
NICE Recommends Santhera’s AGAMREE® for NHS Use, Transforming DMD Treatment
Key Highlights:AGAMREE® (vamorolone) has been recommended by NICE for use in the UK’s National Health Service (NHS) for Duchenne muscular dystrophy (DMD) patients...
Cosmos Health Acquires Two Patented Anticancer Drugs for Prostate, Ovarian, and Colorectal Cancers
Key TakeawaysCosmos Health secures exclusive licensing and buy-out rights for two innovative anticancer drugs, targeting prostate, ovarian, and colorectal cancers.
The drugs are...
ENA Respiratory Advances Antiviral Nasal Therapy with Successful Phase Ib Trial Completion
Key TakeawaysENA Respiratory has successfully completed Phase Ib dosing of its INNA-051 dry powder formulation in older adults aged 60+, demonstrating safety and...
Jaguar Health Doses First Patient in Trial for Rare Pediatric Disease
Key TakeawaysJaguar Health has initiated an investigator-initiated trial (IIT) for crofelemer in microvillus inclusion disease (MVID).
The study is being conducted at Sheikh...
LEO Pharma and DEBRA Research Partner to Develop Epidermolysis Bullosa Treatments
Key TakeawaysLEO Pharma and DEBRA Research have announced a strategic partnership to accelerate the development of new treatments for Epidermolysis Bullosa (EB).
This...
Cosmos Health Files AI-Driven Patent for Allergy Treatment
Key TakeawaysCosmos Health has filed a patent application for an AI-discovered allergic inflammation therapy.
The company’s Cloudscreen AI platform identified a repurposed drug...
Philogen’s Soft Tissue Sarcoma Trial Moves Closer to Key Results
Key TakeawaysPhilogen and Sun Pharma have completed patient enrollment for the Phase III FIBROSARC trial in soft tissue sarcoma (STS).
The trial results...
Jabil Expands Pharma Capabilities with Acquisition of Pii
Key TakeawaysJabil Inc. has acquired Pharmaceutics International, Inc. (Pii) to enhance its pharmaceutical manufacturing capabilities.
The deal strengthens Jabil’s contract development and manufacturing...
Jaguar Health Explores Solution for GLP-1 Drug Side Effects
Key TakeawaysJaguar Health has filed a patent application for crofelemer to address gastrointestinal side effects of GLP-1 weight loss drugs.
Up to 85%...
Filament Health’s Psilocybin Drug to Be Studied in FDA-Approved Trials at UW-Madison
Key TakeawaysFilament Health has shipped its botanical psilocybin drug candidate, PEX010, to UW-Madison for two FDA-approved clinical trials.
The research will focus on...
